Multi-ligand simultaneous docking of Carica papaya leaf phytochemicals, Carpaine and Rutin, reveals multi-mechanism inhibition of cancer proteins BCL-2 and WWP1
Abstract
Cancer remains a major global health concern due to chemotherapy resistance and toxicity from high-dose treatments. To overcome these challenges, new therapeutic strategies targeting key proteins in cancer progression are essential. This study evaluates two phytochemicals, Carpaine (Car) and Rutin (Rut), from Carica papaya leaves, for their potential in enhancing cancer therapy by targeting B-cell lymphoma 2 (BCL-2) and WW domain-containing protein 1 (WWP1) proteins. We assessed their additive, allosteric, and synergistic effects using molecular docking, multi-ligand simultaneous docking (MLSD), molecular dynamics (MD) simulations, and MMPBSA analysis. Car and Rut showed an additive effect on BCL-2 by binding at distinct regions within the same pocket. MLSD revealed an improved binding affinity of -13.13 +/- 0.08 kcal/mol, compared with individual ligands or the commercial inhibitor Venetoclax. For WWP1, Car bound near the H-site and Rut near the Le-site, exhibiting an allosteric effect that increased Car's binding affinity in MLSD to -15.59 +/- 0.39 kcal/mol. Furthermore, Rut combined with bortezomib (Bort) demonstrated a synergistic interaction with WWP1. Binding energies were -7.64 +/- 0.156 kcal/mol for Bort, -10.26 +/- 0.07 kcal/mol for Rut, and -15.59 +/- 0.39 kcal/mol for MLSD, suggesting a more stable complex through synergy. These results suggest Car and Rut, particularly in combination with Bort, as promising candidates against cancer-related proteins BCL-2 and WWP1. Further experimental validation is warranted to explore their therapeutic potential.
Versions
Related
- Special Issue “Molecular Mechanism Discovery of the Bioactive Phytochemicals against Different Diseases Based on Network Pharmacology and Molecular Docking, 2nd Edition”
- Investigating the anticancer potential of phytochemicals from the mangrove Rhizophora mucronata as inhibitors of lung cancer-associated proteins: Insights from multiscale computational and in silico analyses
- Electrostatic Encoding Enables Simultaneous Dual Labeling of Proteins by a Single Sortase A Enzyme
- Structural basis for loop-dependent inhibition by AcrIIC1 anti-CRISPR proteins
- Molecular Mechanism of Lipid Recognition and Membrane-Guided Gating in Plant Minimal START Proteins
BibTeX
@misc{sudha2026multiligand,
title = {{Multi-ligand simultaneous docking of Carica papaya leaf phytochemicals, Carpaine and Rutin, reveals multi-mechanism inhibition of cancer proteins BCL-2 and WWP1}},
author = {Merla Sudha and Asmita Saha and Belaguppa Manjunath Ashwin Desai and Anil Ranu Mhashal and Pronama Biswas},
howpublished = {arXiv},
year = {2026},
month = sep,
doi = {10.48550/arxiv.2609.08547},
eprint = {2609.08547},
archivePrefix = {arXiv},
url = {https://arxiv.org/abs/2609.08547},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - UNPB
TI - Multi-ligand simultaneous docking of Carica papaya leaf phytochemicals, Carpaine and Rutin, reveals multi-mechanism inhibition of cancer proteins BCL-2 and WWP1
AU - Merla Sudha
AU - Asmita Saha
AU - Belaguppa Manjunath Ashwin Desai
AU - Anil Ranu Mhashal
AU - Pronama Biswas
PY - 2026
DA - 2026/09/08
PB - arXiv
DO - 10.48550/arxiv.2609.08547
UR - https://arxiv.org/abs/2609.08547
AB - Cancer remains a major global health concern due to chemotherapy resistance and toxicity from high-dose treatments. To overcome these challenges, new therapeutic strategies targeting key proteins in cancer progression are essential. This study evaluates two phytochemicals, Carpaine (Car) and Rutin (Rut), from Carica papaya leaves, for their potential in enhancing cancer therapy by targeting B-cell lymphoma 2 (BCL-2) and WW domain-containing protein 1 (WWP1) proteins. We assessed their additive, allosteric, and synergistic effects using molecular docking, multi-ligand simultaneous docking (MLSD), molecular dynamics (MD) simulations, and MMPBSA analysis. Car and Rut showed an additive effect on BCL-2 by binding at distinct regions within the same pocket. MLSD revealed an improved binding affinity of -13.13 +/- 0.08 kcal/mol, compared with individual ligands or the commercial inhibitor Venetoclax. For WWP1, Car bound near the H-site and Rut near the Le-site, exhibiting an allosteric effect that increased Car's binding affinity in MLSD to -15.59 +/- 0.39 kcal/mol. Furthermore, Rut combined with bortezomib (Bort) demonstrated a synergistic interaction with WWP1. Binding energies were -7.64 +/- 0.156 kcal/mol for Bort, -10.26 +/- 0.07 kcal/mol for Rut, and -15.59 +/- 0.39 kcal/mol for MLSD, suggesting a more stable complex through synergy. These results suggest Car and Rut, particularly in combination with Bort, as promising candidates against cancer-related proteins BCL-2 and WWP1. Further experimental validation is warranted to explore their therapeutic potential.
ER -